Kornimate/medical-research-clean huggingface dataset:
management of infant digestive disorders and quality of life

Conditions: Infant Nutrition Disorders; Gastrointestinal Dysfunction

Summary: the objective of the study is to measure the evolution of the quality of life in infants between 0 and 5 months old, not breastfed and suffering from regurgitation or colic.

the objective of the study is to measure the evolution of the quality of life in infants between 0 and 5 months old, not breastfed and suffering from regurgitation or colic, following nutritional management of these disorders by a preparation for thickened infants, reduced in lactose content and supplemented with lactobacillus reuteri dsm 17938. quality of life is assessed using the qualin questionnaire

Eligibility criteria:
inclusion criteria: full-term infants (\> 37 weeks gestation and \<42 weeks gestation), less than 4 months of age at recruitment * infants with regurgitation and / or colic defined according to rome iv criteria * non-breastfed infants * parents who understand and speak french fluently * parents agreeing to send their email address and having a computer tool (computer, tablet or smartphone) allowing them to complete the qol questionnaires and the satisfaction questionnaire * parents having understood the protocol and the information given and having given the participation agreement including their acceptance to return for consultation with the same doctor after a period of 30 days. exclusion criteria: infant born prematurely (\<37 weeks) • intercurrent pathology other than a functional intestinal disorder which can by themselves cause, directly or as a result of treatments, a functional intestinal disorder: study management of infant digestive disorders and quality of life * food allergy * digestive pathology (gastroenteritis, celiac disease, high or low digestive malformations....) * heart failure, cyanogenic heart disease * chronic respiratory diseases (bronchopulmonary dysplasia, malformations, respiratory failure) * neurological pathologies (cerebral palsy, intracranial hypertension, convulsive state) * congenital metabolic pathologies * genetic diseases * kidney malformations, vesicoureteral reflux, kidney failure. * drug treatment in progress and which will be continued during the study, other than vitamins (d, k, ...) * partial or total breastfeeding * infants already fed: * with a hypoallergenic formula (ha) * or with a high hydrolyzate of cow's milk proteins or formula based on rice protein hydrolyzate * growth retardation (weight and or height less than or equal to - 2 ds) or break in the weight curve (no weight gain or weight loss in the past month) prescription of drugs or food supplements other than vitamins at the end of the visit

Keywords: quality of life infants regurgitation colic
patient preference and visual quality with contralateral synergy versus panoptix

Conditions: IOL; Cataract; Patient Satisfaction

Summary: the goal of this study is to compare the visual quality and patient preference of the synergy iol versus the panoptix iol when one of each lens is placed in the same patient.


Eligibility criteria:
inclusion criteria: * bilateral cataracts for which phacoemulsification extraction and posterior iol implantation have been planned for both eyes * desire to mitigate postoperative presbyopia with implantation of synergy iol in one eye and panoptix trifocal iol in the opposite eye exclusion criteria: * any vision-limiting problems (e.g., corneal, retinal, infection) which can potentially limit post-operative visual performance * any ocular condition or trauma that is not resolved, stable, or would compromise the well-being of the subject
bestbrain evaluation of cognitive memory & executive-function

Conditions: Mild Cognitive Impairment

Summary: this study is intended 1. to quantify the effects of the iremember personalized eeg-nfb therapy on working memory and executive functions in subjects with mci by calculating the percentage of change in the neurotrax tests performed prior to and after the treatment, and compare the results between the active treatment and placebo cohorts

by using the bestbrain iremember eeg-nfb system, subjects within the "treatment" arm of this clinical investigation will show improvement in working memory, executive functions and general improvement in daily life based on standard accepted cognitive tests such as the neurotrax and kielhfner questionnaire. this hypothesis will be accepted or rejected based on the statistical analysis of the data collected . subjects will be randomized either to the treatment or placebo groups. each subject will undergo an initial and final assessment using neurotrax and specified questionnaires prior to and after 20 treatments. the first sessions will be dedicated to subject evaluation. each subject will undergo either a neurofeedback (nfb) or sham treatment.

Eligibility criteria:
inclusion criteria: 1. male or female age 50-80 years 2. subjects diagnosed with mci, according to the icd-10 criteria. 3. moca score 18 to 25 4. ability to operate a computer mouse and keyboard as evaluated by the clinician. 5. agreement to participate in approximately 12 weeks during the study. 6. normal to near-normal vision and hearing with correction as needed (e.g. corrective lenses, hearing aid). 7. fluent in hebrew 8. willing to participate twice a week for treatments exclusion criteria: 1. participation in a clinical trial with any investigational agent within 6 months prior to study enrollment 2. subjects with one or more of the following disorders in their medical files: psychotic disorder, currently active depression, with a history of bipolar disorder, adjustment disorder, somataform disorder, anxiety disorder ocd, ptsd. (following the axis-1 disorders listed in the icd-10) 3. alcoholism or drug addiction as defined by icd-10 within last 5 years (addicted more than one year and or in remission less than 3 years) or severe sleep deprivation 4. subjects with personal history of a clinically defined neurological/psychiatric disorder including (but not limited to): epilepsy, dementia, clinical stroke (hemiparesis, hemianopsia) , substance abuse, extra pyramidal disorders like parkinson etc) , major head trauma, multiple sclerosis; or personal history of previous neurosurgery or head trauma that resulted in loss of consciousness; use of any medication with the aim to improve cognition (cholinesterase inhibitors).

Keywords: mci early ad
protection from pulmonary embolism with the permanent optease™ filter (proof)

Conditions: Pulmonary Embolism

Summary: the main objective of this study is to monitor the safety and effectiveness of the optease™ permanent vena cava (ivc) filter


Eligibility criteria:
inclusion criteria: * · pulmonary thromboembolism when anticoagulants are contraindicated. * failure of anticoagulant therapy in thromboembolic diseases. * emergency treatment following massive pulmonary embolism where anticipated benefits of conventional therapy are reduced. * chronic, recurrent pulmonary embolism where anticoagulant therapy has failed or is contraindicated. exclusion criteria: * · patients with risk of septic embolism. * patients with uncontrolled infectious disease. * patients with an ivc diameter \> 30 mm. * patients contraindicated for procedures under fluoroscopy. * patients with demonstrated hypersensitivity to one or more of the components of the optease™ filter
safety and efficacy of intravenous immune globulin in treating spinocerebellar ataxia

Conditions: Spinocerebellar Ataxia

Summary: this is a preliminary study to determine the safety and efficacy of intravenous immune globulin in treating spinocerebellar ataxia. the investigators aim to assess changes in clinical measures of disease severity before and after treatment.


Eligibility criteria:
inclusion criteria: 1. outpatients with sca diagnosed by a movement disorder specialist. 2. age 10 years to 80 years. 3. able to ambulate with or without assistance for 30 feet. 4. women of child-bearing potential must use a reliable method of contraception and must provide a negative pregnancy test at entry into the study. 5. serum creatine kinase, complete metabolic panel, complete blood count, liver function tests, renal function tests, platelets and ekg do not reveal clinically significant abnormalities (results obtained from primary care physician and dated within the past 6 months or obtained at screening visit). 6. stable doses of all medications for 30 days prior to study entry and for the duration of the study. 7. stable doses of all antidepressants and vitamins (including internet purchased idebenone) for 30 days prior to study entry and for the duration of the study. throughout the study, all possible efforts should be made to maintain stable doses of all other medications. 8. subject permission (informed consent). exclusion criteria: 1. any unstable illness that in the investigator's opinion precludes participation in this study. 2. use of any investigational product within the past 30 days. 3. presence of clinically significant cardiac disease (as determined by the investigator based on ekg and echocardiogram results within the past 6 months). specifically, an ejection fraction \ 50% of cycle duration) will be excluded. if the investigator notes clinically significant abnormalities on the ekg or echocardiogram, the subject will be eligible if they provide clearance from a cardiologist. 4. presence of diabetes (as determined by blood glucose labs within the past 6 months). 5. dementia or other psychiatric illness that prevents the subject from giving informed consent (mmse less than 25). 6. legal incapacity or limited legal capacity. 7. presence of severe renal disease (estimated creatinine clearance \ 2x times normal) (as evidenced by labs reported within the past 6 months). 8. clinically significantly abnormal wbc, hemoglobin or platelet count (as evidenced by labs reported within the past 6 months). 9. iga deficiency (evidenced by screening lab evaluations)
perineural dexmedetomidine and femoral nerve block

Conditions: Onset and Duration of Sensory and Motor Block of Femoral Nerve,; Visual Analogue Pain Scores,; Time to First Request of Rescue Analgesics,; Total Morphine Consumption in 24 Hours

Summary: the duration of sensory block after single dose of long acting local anesthetics is not sufficient to avoid the postoperative use of opioids. alpha-2 adrenoceptor agonists such as clonidine have been shown to increase the duration of peripheral nerve block. dexmedetomidine is a more potent and selective α-2-adrenoceptor compared to clonidine. to the best of our knowledge, the use of dexmedetomidine as adjuvant to local anesthetic was not previously reported for femoral nerve block.


Eligibility criteria:
inclusion criteria: * all patients with asa physical status i or ii, scheduled for diagnostic knee arthroscopy exclusion criteria: * patients who are refusing regional block, patients with diabetic peripheral neuropathy, renal or hepatic dysfunction, inflammation or infection at the puncture site, and history of allergic reaction to study medications

Keywords: femoral nerve block peri-neural dexmedetomidine
statin therapy in acute influenza

Conditions: Influenza

Summary: influenza (the 'flu') is a common virus infecting approximately 5-20% of the population in the united states and causing as many as 500,000 deaths worldwide each year. currently, there are only a few treatments for influenza infection and none of these target inflammation that can be caused by the virus. this study will test whether the anti-inflammatory effects of statins, a class of drugs most often used to treat high cholesterol, will decrease the severity of illness in patients who are infected with influenza by testing markers of inflammation in the blood and recording resolution of influenza illness.


Eligibility criteria:
inclusion criteria:(all must be present): 1. adult patient (age \> 18 years) 2. positive influenza dfa/rat test result 3. \<12 hours from positive influenza test result exclusion criteria: 1. prior statin medication use (within 30 days of positive influenza test result) 2. comfort measures only designation or anticipated withdrawal of life-support 3. atorvastatin specific exclusions: 1. documented liver cirrhosis or liver dysfunction (ast or alt greater than 240) 2. known allergy or intolerance to statins 3. rhabdomyolysis (cpk elevation \> 6x normal) 4. patients taking the following medications: cyclosporine, hiv protease inhibitors, hepatitis c protease inhibitor telaprevir, fibric acid derivatives (gemfibrozil), niacin, azole antifungals (itraconazole, ketoconazole) clarithromycin and colchicine 4. patients unable to take oral or nasogastric medications or plan for no oral intake as part of medical course (eg. emergent surgical intervention) 5. known pregnancy or active breastfeeding 6. inability to provide written informed consent for any reason
dose escalation and dose expansion study of ipn60090 in patients with advanced solid tumours

Conditions: Solid Tumor

Summary: the purpose of the protocol is to determine safety, tolerability, recommended dose (rd), pharmacokinetics (pk), pharmacodynamics (pd) and preliminary anti-tumour activity of ipn60090 as a single agent (part a) and in combination with pembrolizumab (part b) or paclitaxel (part c) in patients with advanced solid tumours and to evaluate food effect (part d).


Eligibility criteria:
inclusion criteria: * male or female patients ≥18 years of age * patients with solid tumours who have received at least one line of therapy for advanced disease * measurable or non-measurable evaluable disease per recist 1.1 * eastern cooperative oncology group (ecog) performance status (ps) ≤1 * standard of care and/or any investigational therapies must have been completed at least 3 weeks prior to treatment exclusion criteria: * prior malignancy within the previous 2 years except for locally curable cancers that have been cured, such as basal or squamous cell skin cancer, or carcinoma in situ of the cervix, breast or bladder * known primary central malignancy or symptomatic central nervous system metastasis * major surgical intervention within 28 days before study drug administration * significant acute or chronic infections
randomized, controlled study to investigate the effect of neuromuscular electrical stimulation (nmes) on muscle metabolism of abdominal surgical patients

Conditions: Muscular Atrophy

Summary: skeletal muscle atrophy is associated with catabolic conditions such as major surgical interventions and leads to reduced muscle strength, increased clinical complications and prolonged convalescence. several studies revealed immobilisation as a major stimulus for muscle wasting in severely ill patients. this study investigates the potency of neuromuscular electrical stimulation on skeletal muscle growth factors and degradation processes in major abdominal surgery patients.


Eligibility criteria:
inclusion criteria: * intended for major abdominal surgery * more than 18 years old exclusion criteria: * neuromuscular diseases * immobility before surgery * arterial occlusive disease fontaine stadium iv * clinical or laboratory signs of inflammation or sepsis * cachexia * diseases of the musculoskeletal systems contraindicating electrical stimulation

Keywords: skeletal muscle ubiquitin proteasome igf-1 mgf protein catabolism neuromuscular electrical stimulation investigate effect of nmes on muscle metabolism of catabolic patients
is the dynamic of the pelvic bone altered after a total hip replacement ?

Conditions: Coxarthrosis; Primary; Coxarthrosis; Secondary

Summary: total hip replacement is one of the most common surgical procedure in france. in 2010, an estimated 147 513 total hip procedures were performed. this number is constantly increasing. although it is common, it can lead to many complications. the intra-prosthetic luxation is the second one after aseptic loosening. the luxation risk is multifactorial and depends on the relative orientation of femoral et acetabular components. this orientation is influenced by statics and dynamics parameters. so far, the literature shows that only static parameters are considered by surgeons. thus, in reference to lewinneck publication, which states that the luxation risk is lower if the cup is oriented with 15° +/- 10° of anteversion and 40°+/- 10° of inclination with respect to the anterior pelvic plan (app). defined by the two anterosuperior iliacs spines and pubic symphysis. however, this approach is only static and do not take into account the variations of pelvic plan orientation during everyday life. to consider these variations of pelvic inclination, it is possible to measure the angle between app and the horizontal (in lying position) or the vertical (in standing position) plan. several devices allow the measure of pelvic inclination but they all have important limits (eos radiography, scanner or navigation). a new device has been developed in brest to measure this inclination in several positions of the daily life.this software has already been tested in healthy volunteers and results demonstrate an excellent accuracy and reproducibility. the goal of this study is to described the dynamic of the pelvic bone thanks to this ultrasound based device, and to assess the amount of variation induced by hip replacement procedures.


Eligibility criteria:
inclusion criteria : * patient with primary or secondary hip arthritis, at stage ii to iii of the radiological classification of tönnis and for whom total hip replacement is indicated by surgeon. * signed consent * patient beneficiary of a social security plan exclusion criteria: * patient under 18 * patient under protective measure (guardianship, curatorship) or unable to consent * patient requiring revision thr * patient with geographic mobility plan before the end of the follow-up * symptomatic contralateral hip * symptomatic dorsolumbar rachis * pelvis or spine surgery planed during the follow-up * pregnant or nursing woman
impact of bladder underactivity on treatment outcomes of laser prostatectomy

Conditions: Prostatic Hyperplasia

Summary: the aim of this study was to evaluate an impact of preoperative bladder underactivity on treatment outcomes of photoselective vaporization of the prostate (pvp) or holmium laser enucleation of the prostate (holep) in the treatment of benign prostatic obstruction, and to compare it between the two types of surgery for benign prostatic hyperplasia.


Eligibility criteria:
inclusion criteria: * patients in whom 12-month follow-up data were available exclusion criteria: * a previous diagnosis of urethral stricture * prostate or bladder carcinoma * neurogenic bladder disease * a previous history of urological surgery
sirolimus in covid-19 phase 1

Conditions: SARS-CoV-2; Covid-19

Summary: this is a double-blinded, two-arm, randomized, placebo controlled study comparing the virological efficacy of add-on sirolimus with standard care to placebo and standard care. virological efficacy is defined as the change from baseline to day 7 in sars-cov-2 viral burden measured by quantitative real-time polymerase chain reaction.


Eligibility criteria:
inclusion criteria: * male or non-pregnant female \>/=18 and \</=65 years of age at the time of consent * laboratory confirmed sars-cov-2 infection * investigator-estimated hospitalization duration of at least 5 days exclusion criteria: * need for \>4 liters nasal cannula oxygen to maintain oxygen saturation \>90% * hypersensitivity to sirolimus * pregnant or breastfeeding * anticipated transfer to another study hospital within 72 hours * alanine transaminase (alt) \>3 times the upper limit of normal * creatinine clearance \<30ml/min as estimated by cockcroft-gault * underlying immunosuppression due to daily \>5 mg prednisone equivalent a day, prior solid organ transplant, or other immunosuppression deemed by investigator to be potentially unsafe * co-administration with strong inhibitors of cyp3a4 and/or p-glycoprotein (p-gp) (such as ketoconazole, voriconazole, itraconazole, telithromycin, clarithromycin and others) * co-administration with strong inducers of cyp3a4 and/or p-glycoprotein (p-gp) (such as phenytoin or rifampin) * anticipated surgery within 1 month * need for healing of a fracture or a significant soft tissue wound
outpatient office based endovascular procedures

Conditions: Chronic Venous Insufficiency; Peripheral Arterial Disease; Dialysis Access Malfunction; Arterio-venous Fistula; Thoracic Outlet Syndrome; Vertebral Artery Insufficiency; Varicose Veins

Summary: the results of this study will serve as a starting point for future trials concentrating on the effectiveness and clinical outcomes of the procedures performed in an office based angiosuite. additionally, other studies could compare clinical outcomes between procedures performed in an office based angiosuite and other settings.

endovascular surgery combined with the demands of patients and physicians for less invasive procedures, have make this type of surgery one of the most innovative fields in medicine. however the endovascular experience in an office-based angiosuite is different from that in a hospital suite, and has been viewed in the past by some physicians as unsafe because it lacks the safety net of immediate hospital resources. in 2005, medicine allowed endovascular procedures to be performed in the office setting. the results of this study will serve as a starting point for future trials concentrating on the effectiveness and clinical outcomes of the procedures performed in an office based angiosuite.

Eligibility criteria:
inclusion criteria: * age ≥ 18 years. * diagnosis of peripheral arterial disease (pad), chronic venous insufficiency, dialysis access and malfunctioning arteriovenous fistulas, varicose veins, vertebrobasilar insufficiency, and thoracic outlet syndrome. * procedures performed as an outpatient in an office based angiosuite. exclusion criteria: * age ≤ 18 years

Keywords: office based angiosuite
effects of ipv assessed with functional imaging

Conditions: Chronic Obstructive Pulmonary Disease

Summary: in this study the invetigators seek an answer on the following hypothesis: * what are the long term effects of an ipv treatment evaluated with classical outcome parameters? (fev1, raw) * is the possible effect noticeable on the novel technique and is this comparable with the classical outcome parameters?

a multicenter study conducted in university hospital antwerp (uza) and zna middelheim. tests are taken before and after one week ipv treatment. ipv is applied for 1 week during the physical therapy treatment of chronic obstructive pulmonary desease (copd) patients admitted to the hospital for an excarebation. the ipv treatment is an additional treatment upon the standard treatment of the patients. the standard treatment consists out of existing drainage techniques to remove secretion out of the lungs by means of breathing control exercises. patients are randomized into either the experimental group or the control group. the control group receives a standard physical therapy treatment without additional ipv treatment.

Eligibility criteria:
inclusion criteria: * patients admitted in the hospital for a acute exacerbation * mild to severe copd exclusion criteria: * ischemic / ventricular aritmic * tracheotomise * pneumothorax * facial deformity * recent nose, mouth or ear operations * recent gastric operations. * intubated * epilepsy

Keywords: copd ipv